ORYZON Reports First Quarter 2016 Financial Results and Corporate Update

Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today reported financial results for the first quarter of 2016 and provided a corporate update on the Company’s recent developments.

Oryzon has invested €1.2 million in research and development during the first quarter of 2016. The company’s equity increased by €14.6 million since the first quarter of 2015, reaching now a total of €27.8 million, €21.9 million of which comes from their own funds.

Research and development expenses in the first quarter of 2016 have allowed the Company to move forward in the early phase resea rch programs, and to get ORY - 2001 ready to begin a Phase I clinical trial for Alzheimer ’s , after receiving approval from the Spanish Health Authority. Oryzon now has two different “first in class epigenetic molecules in clinical trials in humans. I t is important to highlight the progress of ORY - 1001 in the ongoing Phase I/IIA clinical trial as new patients have been recruited in France and the United Kingdom.

At the close of the first quarter of the present financial period, the sum of the cash an d the short - term investments (€29 million) has increased by €7.3 million since the end of 2015 . These figures demonstrate the financial consolidation of the c ompany and serve as guarantee for research activities for the rest of the year .

In terms of accumu lated losses , Oryzon has accounted capital net losses amounting to €0.6 million. In comparison , during the same quarter of the previous year, the company accounted losses of €0.5 million.

Carlos Buesa, CEO of Oryzon, commented that “the company had a successful first quarter of 2016, a period marked by the approval of ORY - 2001 Phase I clinical trial and a new significant investment in R&D. It is important to consider that business models in the biotechnology industry must be assessed on the front of th eir advances in scientific programs, investment in R&D and their capacity to generate funds to continue working on programs to be licensed to big pharmaceutical multinationals.”

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES01677 33015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche . Oryzon’s LSD1 program is currently cove red by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification a nd performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case - by - case basis to either keep the development in - house or to partner or out - license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.